GE HealthCare’s commitment to advancing precision care in cardiology through its molecular imaging solutions will be on display at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana.
June 23, 2025 — Susan G. Komen, the world’s leading breast cancer organization, recently announced it is awarding $10.8 million in new research grants that will help propel innovative science and deliver hope to those facing the disease. These research grants support 25 cutting-edge projects at 17 prestigious institutions — marking a powerful commitment to improving outcomes for people living with breast cancer today and in the future.
June 23, 2025 — Serac Imaging Systems Ltd. and its clinical investigators from The Ohio State University Wexner Medical Center, U.S. and the Faculty of Medicine at the University of Malaya, Malaysia, have announced that posters featuring clinical trials directed using Seracam are being presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in New Orleans, U.S.
June 17, 2025 — Bayer has announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane for contrast-enhanced magnetic resonance imaging of the CNS and other body regions in adults and pediatric patients including term neonates. The submitted dose is 0.04 mmol gadolinium per kilogram body weight. If approved, gadoquatrane would become the lowest dose macrocyclic GBCA available in the U.S., corresponding to a 60 percent reduction compared to macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight.
June 19, 2025 — Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine — with one of the key intentions being the development and research of innovative total body PET/CT technology.i This effort is expected to explore new clinical pathways and help enhance patient outcomes through innovative imaging solutions.
June 17, 2025 — Royal Philips has announced the global launch of the Flash Ultrasound System 5100 POC — a new point-of-care (POC) ultrasound system engineered for the fast-moving needs of anesthesia, critical care, emergency medicine and musculoskeletal imaging. Built on Philips’ established foundation of cardiology and general imaging ultrasound technology, Flash 5100 POC combines exceptional image clarity, smart automation and intuitive touchscreen controls in a highly portable system that supports rapid, confident decision-making for users of all experience levels.
June 19, 2025 — Naitive Technologies has published results demonstrating the diagnostic performance of its AI-powered tool, OsteoSight, for identifying people at risk of low bone mineral density (BMD).
The results, published in Osteoporosis International, validate the utility of OsteoSight in detecting low BMD using routine X-rays that have been taken for other purposes.
June 18, 2025 — Exo recently announced that now included on its Exo Iris is the first ever FDA 510(k) cleared AI for detecting pleural effusion and consolidation/atelectasis. These on-device real-time indicators empower clinicians with objective data to help detect lung diseases like pneumonia and tuberculosis at the bedside in seconds.
In breast cancer detection, speed and accuracy are more than clinical goals – they can significantly increase chances for cure and impact treatment paths and outcomes. Too often, women face barriers to advanced imaging due to cost, access, or availability. As healthcare systems seek solutions that empower providers and improve patient outcomes, one innovation is taking shape as a powerful ally: contrast-enhanced digital mammography (CEDM).
If you enjoy this content, please share it with a colleague
May 6, 2025 — NewVue.ai and MD.ai have announced an integration partnership that brings MD.ai’s structured reporting platform into NewVue’s EmpowerSuite.